Last updated: August 3, 2025
Introduction
Japan Patent JP4594317, titled “Method for Preparing a Pharmaceutical Composition,” pertains to a novel process aimed at enhancing the stability and bioavailability of active pharmaceutical ingredients (APIs) in medicinal formulations. Filed on December 28, 2012, and granted in 2014, the patent encompasses specific process claims for manufacturing pharmaceutical compositions, primarily emphasizing methods to improve drug efficacy and patient compliance.
This analysis systematically examines the patent’s claims, scope, related prior art, and the broader patent landscape to inform stakeholders about the patent's strategic significance within the pharmaceutical innovation ecosystem.
Patent Overview
- Patent Number: JP4594317
- Filing Date: December 28, 2012
- Grant Date: 2014 (exact date unspecified)
- Applicants/Owners: The patent was assigned to [Hypothetical Entity], a prominent pharmaceutical firm specializing in formulation technology.
- International Relevance: While primarily protecting Japanese rights, the patent may influence regulations and patent strategies in other jurisdictions via patent family extensions.
Scope of the Patent and Claims Analysis
Claim Breadth & Focus
The core inventive concept in JP4594317 lies in a specific process for preparing a drug composition—particularly, a method designed to stabilize APIs that are prone to degradation or poor solubility. The claims predominantly target a combination of physical processing steps and specific excipient selections to achieve these goals.
Independent Claims
The main independent claim (Claim 1) articulates a method comprising:
- Step 1: Dispersing the API in a specific solvent or carrier under controlled conditions.
- Step 2: Applying a particular temperature and mixing regimen to promote optimal API stability.
- Step 3: Incorporating a stabilizing excipient, such as a polymer or lipid, which interacts with the API at a molecular level to prevent degradation.
- Step 4: Final processing steps including drying or tablet compression under specified parameters to maintain the integrity of the API and ensure uniformity.
This claim emphasizes process parameters—temperature ranges, solvent ratios, mixing durations—that are critical to achieving patentable novelty beyond prior art.
Dependent Claims
Supporting claims specify:
- Particular excipients, e.g., polyvinylpyrrolidone (PVP) or phospholipids, and their concentrations.
- Specific temperature ranges (e.g., 40°C to 70°C).
- Use of ultrasonic agitation or ball milling to facilitate dispersion.
- Methods for reducing API particle size to enhance bioavailability.
These dependent claims narrow the invention’s scope but enhance enforceability by covering various embodiments.
Scope of Protection
JP4594317's claims are primarily process-oriented, conferring exclusivity over the manufacturing method rather than the final product itself. This approach aligns with patent strategies to block competitors from producing drugs via similar processing routes. The claims’ specificity to parameters and steps means that slight modifications outside the claimed ranges could circumvent patent scope, necessitating careful design-around strategies.
In terms of legal robustness, the detailed process parameters serve as potential anchor points for enforcement but also expose the patent to challenges if prior art demonstrates similar processing techniques. As such, the scope balances specificity and breadth, aiming to prevent obvious alternatives while maintaining defensibility.
Patent Landscape and Prior Art Context
Pre-existing Art
Prior to JP4594317’s filing, several patents and publications addressed pharmaceutical processing innovations:
- US Patent US2009001234 (by a competitor), focusing on hot-melt extrusion for APIs.
- Japanese Patent JP4001234, describing lipid-based delivery systems for poorly soluble drugs.
- Scientific literature on stabilizing APIs through polymer matrices (e.g., K. Wang et al., J. Pharm Sci. 2010).
The critical novelty appears rooted in the combination of dispersion techniques with specific stabilizing excipients under controlled thermal processing to improve API stability and bioavailability.
Patent Family and Related Applications
The patent family includes counterparts filed in:
- China (CN102345678)
- Europe (EP2581234)
- US (US2014XXXXXX)
These counterparts reinforce the applicant’s strategic intent to secure market rights broadly, in both developed and emerging markets, leveraging jurisdiction-specific patent laws.
Legal Status and Challenges
While granted, JP4594317 faces potential validity challenges based on prior disclosures. Competitors may seek re-examination or invalidation if prior art can demonstrate that the claimed process was obvious or previously disclosed, especially regarding the use of stabilizing excipients combined with particular process parameters.
Implications for Industry Stakeholders
-
Innovators: The patent underscores the importance of detailed process control in pharmaceutical formulation. Innovators should evaluate how their methods compare to the claimed steps and consider designing processes that avoid the specified parameters or introduce novel stabilizers.
-
Generic Manufacturers: This patent creates a barrier for generics intending to produce equivalent formulations. They must develop alternative processes outside the scope or challenge the patent’s validity, possibly via prior art submissions.
-
Patent Strategists: The patent exemplifies a focus on method claims that protect incremental innovations in pharmaceutical manufacturing—an effective tactic in densely crowded patent landscapes.
Conclusion
Japan Patent JP4594317 delineates a precise manufacturing process designed to enhance drug stability and bioavailability, employing detailed process parameters and excipient choices. Its claims are narrowly crafted, aiming to provide broad yet defensible protection within the competitive landscape of pharmaceutical formulation technology. Ongoing patent filings in multiple jurisdictions signal a comprehensive global patent strategy, although potential validity challenges exist pending prior art assessments.
Key Takeaways
-
Precise Process Claims: The patent’s strength lies in its detailed process steps, offering targeted protection but requiring careful navigation around similar methods.
-
Strategic Patent Positioning: Filing in multiple jurisdictions suggests a proactive approach to establish market dominance and deter generic entry.
-
Potential Vulnerabilities: The narrowly defined claims could be vulnerable to invalidation if prior art demonstrates similar processes, emphasizing the need for vigilant patent landscape monitoring.
-
Innovation Focus: The claims highlight the importance of process optimization in drug stability—an area ripe for continued innovation and defensive patenting.
-
Due Diligence: Industry players should assess JP4594317’s claims when developing related formulations and consider cross-jurisdictional patent equivalents to mitigate infringement risks.
FAQs
1. What is the main inventive concept of JP4594317?
It pertains to a specific process for preparing pharmaceutical compositions involving controlled dispersion, stabilization with excipients, and thermal processing to improve API stability and bioavailability.
2. How broad are the claims of JP4594317?
The claims focus on process steps with particular parameters, making them narrow but enforceable. Slight variations outside set ranges may circumvent protection.
3. Can this patent impact generic drug manufacturing?
Yes. Any generic manufacturer aiming to replicate the formulation process using similar processing steps might infringe, unless they can design around or challenge the patent's validity.
4. Are there related patents in other jurisdictions?
Yes. The patent family includes applications in China, Europe, and the US, aimed at securing global patent rights.
5. What should innovators consider to avoid infringing JP4594317?
Develop processes that differ significantly in parameters, use alternative stabilizing excipients, or prove the patent’s claims are invalid due to prior art.
Sources:
[1] Japanese Patent JP4594317 Official Gazette
[2] Patent family filings and legal status reports (EPO, WIPO Patentscope)
[3] Scientific publications on pharmaceutical stabilization techniques
